Astrazeneca Pharma Q1 Results FY26: Q1 PAT Rises 573.54% to ₹55.83 Crore; Revenue Up 35.81% YoY

Astrazeneca Pharma  Q1 Results FY26: Astrazeneca Pharma posted its Q1 results on 14th August 2025. The company posted robust numbers, with Q1 PAT standing at ₹55.83 crores against revenue of ₹526.31 crores. During Q1 FY26, the profit increase of the company was recorded at 573.54% YoY, and the revenue increase for the same period was 35.81%. 

Astrazeneca Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Astrazeneca Pharma Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Astrazeneca Pharma clocked Q1 FY26 standalone revenue of ₹526.31 crores vs ₹387.52 crores. 
• On the profit front, Astrazeneca Pharma earned a standalone PAT of ₹55.83 crore in Q1 FY26. During FY25, the company’s PAT stood at -₹11.79 crore.
• As per the standalone figures, the quarterly PAT of Astrazeneca Pharma has increased by 573.54%, and revenue has increased by 35.81% YoY.

Astrazeneca Pharma Share Price Performance

On the opening bell of 18th August 2025, the shares of Astrazeneca Pharma opened at ₹8,478.50 per share. However, the initial gains are wiped out as of now, and Astrazeneca Pharma shares are trading at ₹8,421.50 per share, lower than their opening price. 

Considering the long-term performance, Astrazeneca Pharma shares have yielded close to 27.11% returns in the past 1 year, and 5-year returns stand at 150.93%. Over the maximum timeframe, the Astrazeneca Pharma share provided 12,696.69% returns to investors. 

What Analysts Expect Post Q1 Results?

As Astrazeneca Pharma has posted robust Q1 results for FY26, analysts are expecting positive trends in its share price. As per the analysts, Astrazeneca Pharma’s share price could reach ₹9,500.00 per share in the coming year, and in downtrends, the share price could hit the level of ₹7,000.00 per share. However, one must ignore the risk of volatility in the stock market and invest in Astrazeneca Pharma shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Max Healthcare Q1 Results FY26: Q1 PAT Rises 30.35% to ₹307.97 Crore; Revenue Up 31.41% YoY

Minda Corporation Q1 Results FY26: Q1 PAT Rises 1.73% to ₹65.31 Crore; Revenue Up 16.23% YoY

Bharat Dynamics Q1 Results FY26: Q1 PAT Rises 154.30% to ₹18.35 Crore; Revenue Up 29.69% YoY

Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY

Elgi Equipments Q1 Results FY26: Q1 PAT Rises 17.58% to ₹85.60 Crore; Revenue Up 8.19% YoY

Aavas Financier Q1 Results FY26: Q1 PAT Rises 10.41% to ₹139.23 Crore; Revenue Up 15.70% YoY

Regaal Resources IPO GMP: Day 2 IPO Live Updates